Oragenics Inc OGEN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2003-07-09 |
| Shares Out. | 4,510,000 |
| Website | oragenics.com/ ↗ |
| Phone | 18132867900 |
| Employees | 3 |
| Net Income | -$2.2M |
| Total Assets | $7.5M |
| Total Liabilities | $1.3M |
| Equity | $6.2M |
About Oragenics Inc
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Oragenics Inc is a publicly traded company under the ticker symbol OGEN on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)